Phase I Studies of Nivolumab and Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma


Phase I Studies of Nivolumab and Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Michelle A Fanale, MD (2/18/16)
Ansell S et al. Nivolumab in patients (pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): Clinical outcomes from extended follow-up of a phase 1 study (CA209-039). Proc ASH 2015;Abstract 583.

Armand P et al. PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Safety, efficacy, and biomarker assessment. Proc ASH 2015;Abstract 584.

Dr Fanale is Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center in Houston, Texas.